Focus on Adoptive T Cell Transfer Trials in Melanoma

Table 1

Comparison of published adoptive T cell transfer studies for melanoma patients.

	T cell type	Origin of T cell	Culture initiation	In vitro screening	Large-scale expansion protocol	Patient conditioning	OR (%)	Ref
A	TIL	Melanoma biopsy	One single bulk culture	None	Cells grown with IL-2 till desired number obtained	Cyclophosphamide	35	[24, 25]
B	Selected-TIL	Melanoma biopsy	Multiple cultures	IFNγ ELISA	anti-CD3, IL-2, IFC for 14 days	NMC	50	[17, 41]
C	Young-TIL	Melanoma biopsy	One single bulk culture	None	anti-CD3, IL-2, IFC for 14 days	NMC	50	[16]
D	Selected-TIL	Melanoma biopsy	Multiple cultures	IFNγ ELISA	anti-CD3, IL-2, IFC for 14 days	NMC + 2 Gy TBI	52	[18]
E	Selected-TIL	Melanoma biopsy	Multiple cultures	IFNγ ELISA	anti-CD3, IL-2, IFC for 14 days	NMC + 12 Gy TBI	72	[18]
F	Engineere T cells	Leukopheresis	Gene therapy with low-affinity MART-1 TCR	IFNγ ELISA, Transductio efficiency	various protocols	NMC	12	[56]
G	Engineere T cells	Leukopheresis	Gene therapy with high-affinity MART-1 TCR	IFNγ ELISA, Transductio efficiency	various protocols	NMC	30	[60]
H	Engineere T cells	Leukopheresis	Gene therapy with gp100 TCR	IFNγ ELISA, Transductio efficiency	various protocols	NMC	19	[60]

(TIL) Tumor infiltrating lymphocytes, (OR) objective response, (Ref) Reference, (IFC) irradiated feeder cells, (NMC) nonmyeloablative chemotherapy, and (TBI) total body irradiation.